Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant

Pedersen, Court; Petäjä, Tiina; Strauss, Gitte; Rümke, H. C.; Põder, Airi; Richardus, Jan Hendrik; Spiessens, Bart; Descamps, Dominique; Hardt, Karin; Lehtinen, Matti; Dubin, Gary

doi:10.1016/j.jadohealth.2007.02.015

Cited by 219 publications

(167 citation statements)

References 27 publications

Supporting

Mentioning

134

Contrasting

Unclassified

Order By: Relevance

“…Vaccination against oncogenic types of Human Papillomavirus (HPV) is effective in preventing cervical cancer among adolescents if the vaccine was taken before the exposure to HPV (Villa et al, 2005;Pedersen et al, 2007). HPV infection is the most common infection among young and sexually active individuals (Weaver, 2006).…”

Section: Introductionmentioning

confidence: 99%

Knowledge, Attitude and Practice of Malaysian Medical and Pharmacy Students Towards Human Papillomavirus Vaccination

Rashwan¹,

Saat²,

Manan³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Human Papillomavirus (HPV) infection is one of the most common sexually transmitted infections and oncogenic HPV is the main cause of cervical cancer. However, HPV vaccination is already available as the primary preventive method against cervical cancer. The objective of this study was to determine the level of knowledge, attitude and practice of HPV vaccination among Universiti Kebangsaan Malaysia (UKM) and Universiti Malaya (UM) students. This study was conducted from March until August 2009. Pre-tested and validated questionnaires were filled by the third year UKM (n=156) and UM (n=149) students from medical, dentistry and pharmacy faculties. The results showed that the overall level of knowledge on HPV infection, cervical cancer and its prevention among respondents was high and the majority of them had positive attitude towards HPV vaccination. Medical students had the highest level of knowledge (p<0.05). Very few students (3.6%) had already taken the vaccine with no significant difference between the two Universities (p=0.399). In conclusion, the knowledge and attitude of the respondents were high and positive, respectively. Only few students took HPV vaccination. Thus, more awareness campaigns and HPV vaccination services should be provided at universities' campuses with the price of the HPV vaccine reduced for the students.

show abstract

Section: Introductionmentioning

confidence: 99%

Knowledge, Attitude and Practice of Malaysian Medical and Pharmacy Students Towards Human Papillomavirus Vaccination

Rashwan¹,

Saat²,

Manan³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The third dose of the vaccine resulted in four-fold and twofold increase in HPV type 16 18. These responses were also higher than those reported among females 10 to 14 years of age (133) or males 15 to 18 years of age. (132) Immune responses in females following HPV2 administered at 0, 1, 12 months Immune responses to HPV2 (seroconversion rate and GMTs for both HPV type 16 and HPV type 18) administered with the standard 0, 1, 6 schedule compared to the 0, 1, 12 schedule were non-inferior in a randomized controlled trial in 804 healthy young women 15 to 25 years of age in Italy, Romania and Slovakia.…”

Section: Male Immune Response To Three Doses Of Hpv2mentioning

confidence: 75%

Update on Human Papillomavirus (HPV) Vaccines

Dm¹,

Mt²,

Ds³

2012

Canada Communicable Disease Report

View full text Add to dashboard Cite

“…НОВАЯ СХЕМА ВАКЦИНАЦИИ ДЛЯ ДЕВОЧЕК В ВОЗРАСТЕ 9-14 ЛЕТ Многочисленные иммунологические исследования по эффективности бивалентной вакцины показали, что в возрастной когорте девочек в возрасте от 9 до 14 лет содержание антител было приблизительно в 2 раза выше, чем у девушек и женщин 15-25 лет, и оставалось высоким как минимум на протяжении 4 лет [30,31]. Такая высокая иммуногенность вакцины привела к гипо-тезе о возможной двухдозовой схеме иммунизации для лиц младшей возрастной группы.…”

Section: опыт применения бивалентной впч-вакциныunclassified